PREMARIN TEBLET

Women Health

Description
Shipping Options
Customer Reviews

Brand Name: Premarin
Generic Name: Conjugated Estrogens (USP)
Therapeutic Class: Estrogen Replacement Therapy (ERT)
Available Strengths: 0.3 mg, 0.45 mg, 0.625 mg, 0.9 mg, 1.25 mg tablets
Source: Natural estrogens derived from pregnant mares’ urine

2. COMPOSITION

Component	Percentage	Primary Estrogenic Activity
Sodium Estrone Sulfate	50-65%	Weak estrogen
Sodium Equilin Sulfate	20-35%	Moderate estrogen
Other Estrogens (Δ8,9-dehydroestrone)	15-25%	Variable activity

*Note: Contains 10+ estrogenic compounds not found in humans*

3. MECHANISM OF ACTION

Binds to nuclear estrogen receptors (ERα and ERβ)
Genomic effects:
- Upregulates protein synthesis in target tissues
- Maintains secondary sexual characteristics
Non-genomic effects:
- Modulates neurotransmitter activity (hot flash reduction)
- Maintains bone mineral density (osteoporosis prevention)

4. DOSAGE & ADMINISTRATION

Standard Dosing Guidelines

Indication	Starting Dose	Maintenance Dose	Duration
Vasomotor Symptoms	0.3-0.45 mg	Lowest effective dose	≤5 years
Vulvovaginal Atrophy	0.3 mg	May increase to 0.625 mg	Ongoing
Osteoporosis Prevention	0.3-0.625 mg	Long-term (with reevaluation)	≥5 years
Hypoestrogenism	0.3-1.25 mg	Cyclic or continuous	Indefinite

Key Administration Notes

✔ Take at the same time daily ✔ With or without food (food may reduce nausea) ✔ For women with uterus: Must add progestin (e.g., medroxyprogesterone)

5. INDICATIONS

✅ Moderate-to-severe vasomotor symptoms (hot flashes/night sweats) ✅ Vulvovaginal atrophy (when topical therapy inappropriate) ✅ Prevention of postmenopausal osteoporosis ✅ Hypoestrogenism (primary ovarian failure, surgical menopause)

6. STORAGE CONDITIONS

Temperature: 20-25°C (68-77°F)
Humidity: Keep in original bottle with desiccant
Light Protection: Required
Shelf Life: 3 years

7. KEY RECOMMENDATIONS

✔ Use lowest effective dose for shortest duration ✔ Annual monitoring:

Breast exam/mammogram
Endometrial evaluation (if uterus present)
Lipid profile and bone density (if long-term use) ✔ Consider transdermal estrogen for high-risk patients (VTE history)

8. IMPORTANT SAFETY INFORMATION

Black Box Warnings

⚠ Endometrial Cancer:

5-10x risk increase with unopposed estrogen
Requires progestin co-therapy in non-hysterectomized women

⚠ Cardiovascular Risks:

Increased stroke/MI risk in women >60 years
Higher with oral vs. transdermal formulations

⚠ Breast Cancer:

1.24x risk increase after 5+ years of use

Contraindications

❌ Estrogen-dependent neoplasia ❌ Undiagnosed vaginal bleeding ❌ Active/history of thromboembolism ❌ Severe hepatic dysfunction

Adverse Effects

Common (≥5%)	Serious (<1%)
Breast tenderness	Venous thromboembolism
Nausea	Gallbladder disease
Headache	Dementia (in women >65)

9. COMPARISON WITH OTHER ESTROGENS

Parameter	Premarin	Estradiol	Synthetic Estrogens
Source	Equine	Human-identical	Chemical (e.g., EE)
Components	10+ estrogens	Single compound	Single compound
Bone Protection	+++	+++	+
VTE Risk	High	Moderate	Highest

10. PATIENT COUNSELING POINTS

✔ Take missed dose ASAP (unless close to next dose) ✔ Report warning signs immediately:

Breast lumps
Severe headaches
Visual changes
Leg pain/swelling ✔ Non-hormonal alternatives:
SSRIs (for hot flashes)
Bisphosphonates (for osteoporosis)

CONCLUSION

Premarin remains a potent estrogen option with unique equine-derived composition, but requires careful risk-benefit evaluation due to significant safety concerns. Topical therapies or human-identical estrogens may be preferable for many patients.

Brand Name: Premarin
Generic Name: Conjugated Estrogens (USP)
Therapeutic Class: Estrogen Replacement Therapy (ERT)
Available Strengths: 0.3 mg, 0.45 mg, 0.625 mg, 0.9 mg, 1.25 mg tablets
Source: Natural estrogens derived from pregnant mares’ urine

2. COMPOSITION

Component	Percentage	Primary Estrogenic Activity
Sodium Estrone Sulfate	50-65%	Weak estrogen
Sodium Equilin Sulfate	20-35%	Moderate estrogen
Other Estrogens (Δ8,9-dehydroestrone)	15-25%	Variable activity

*Note: Contains 10+ estrogenic compounds not found in humans*

3. MECHANISM OF ACTION

Binds to nuclear estrogen receptors (ERα and ERβ)
Genomic effects:
- Upregulates protein synthesis in target tissues
- Maintains secondary sexual characteristics
Non-genomic effects:
- Modulates neurotransmitter activity (hot flash reduction)
- Maintains bone mineral density (osteoporosis prevention)

4. DOSAGE & ADMINISTRATION

Standard Dosing Guidelines

Indication	Starting Dose	Maintenance Dose	Duration
Vasomotor Symptoms	0.3-0.45 mg	Lowest effective dose	≤5 years
Vulvovaginal Atrophy	0.3 mg	May increase to 0.625 mg	Ongoing
Osteoporosis Prevention	0.3-0.625 mg	Long-term (with reevaluation)	≥5 years
Hypoestrogenism	0.3-1.25 mg	Cyclic or continuous	Indefinite

Key Administration Notes

✔ Take at the same time daily
✔ With or without food (food may reduce nausea)
✔ For women with uterus: Must add progestin (e.g., medroxyprogesterone)

5. INDICATIONS

✅ Moderate-to-severe vasomotor symptoms (hot flashes/night sweats)
✅ Vulvovaginal atrophy (when topical therapy inappropriate)
✅ Prevention of postmenopausal osteoporosis
✅ Hypoestrogenism (primary ovarian failure, surgical menopause)

6. STORAGE CONDITIONS

Temperature: 20-25°C (68-77°F)
Humidity: Keep in original bottle with desiccant
Light Protection: Required
Shelf Life: 3 years

7. KEY RECOMMENDATIONS

✔ Use lowest effective dose for shortest duration
✔ Annual monitoring:

Breast exam/mammogram
Endometrial evaluation (if uterus present)
Lipid profile and bone density (if long-term use)
✔ Consider transdermal estrogen for high-risk patients (VTE history)

8. IMPORTANT SAFETY INFORMATION

Black Box Warnings

⚠ Endometrial Cancer:

5-10x risk increase with unopposed estrogen
Requires progestin co-therapy in non-hysterectomized women

⚠ Cardiovascular Risks:

Increased stroke/MI risk in women >60 years
Higher with oral vs. transdermal formulations

⚠ Breast Cancer:

1.24x risk increase after 5+ years of use

Contraindications

❌ Estrogen-dependent neoplasia
❌ Undiagnosed vaginal bleeding
❌ Active/history of thromboembolism
❌ Severe hepatic dysfunction

Adverse Effects

Common (≥5%)	Serious (<1%)
Breast tenderness	Venous thromboembolism
Nausea	Gallbladder disease
Headache	Dementia (in women >65)

9. COMPARISON WITH OTHER ESTROGENS

Parameter	Premarin	Estradiol	Synthetic Estrogens
Source	Equine	Human-identical	Chemical (e.g., EE)
Components	10+ estrogens	Single compound	Single compound
Bone Protection	+++	+++	+
VTE Risk	High	Moderate	Highest

10. PATIENT COUNSELING POINTS

✔ Take missed dose ASAP (unless close to next dose)
✔ Report warning signs immediately:

Breast lumps
Severe headaches
Visual changes
Leg pain/swelling
✔ Non-hormonal alternatives:
SSRIs (for hot flashes)
Bisphosphonates (for osteoporosis)

CONCLUSION

Shipping Options –

We offer a variety of shipping options, including Express Mail Service (EMS), USPS, DHL, FedEx, TNT, UPS, Aramex, Air Cargo, and sea freight.

Terms and Conditions –

Bulk Orders: You are responsible for any local import duties and taxes in your country.

For Patients: When ordering prescription medicines for personal use, or for a friend or relative, a valid medical practitioner’s script or prescription is required.

Return and Refund Policy: Due to the nature of our products, we cannot accept returns or exchanges once a purchase is made. However, in the event of non-delivery, you are eligible for either a 100% refund or a reshipment of your order.

Description
Reviews (0)

Brand Name: Premarin
Generic Name: Conjugated Estrogens (USP)
Therapeutic Class: Estrogen Replacement Therapy (ERT)
Available Strengths: 0.3 mg, 0.45 mg, 0.625 mg, 0.9 mg, 1.25 mg tablets
Source: Natural estrogens derived from pregnant mares’ urine

2. COMPOSITION

Component	Percentage	Primary Estrogenic Activity
Sodium Estrone Sulfate	50-65%	Weak estrogen
Sodium Equilin Sulfate	20-35%	Moderate estrogen
Other Estrogens (Δ8,9-dehydroestrone)	15-25%	Variable activity

*Note: Contains 10+ estrogenic compounds not found in humans*

3. MECHANISM OF ACTION

Binds to nuclear estrogen receptors (ERα and ERβ)
Genomic effects:
- Upregulates protein synthesis in target tissues
- Maintains secondary sexual characteristics
Non-genomic effects:
- Modulates neurotransmitter activity (hot flash reduction)
- Maintains bone mineral density (osteoporosis prevention)

4. DOSAGE & ADMINISTRATION

Standard Dosing Guidelines

Indication	Starting Dose	Maintenance Dose	Duration
Vasomotor Symptoms	0.3-0.45 mg	Lowest effective dose	≤5 years
Vulvovaginal Atrophy	0.3 mg	May increase to 0.625 mg	Ongoing
Osteoporosis Prevention	0.3-0.625 mg	Long-term (with reevaluation)	≥5 years
Hypoestrogenism	0.3-1.25 mg	Cyclic or continuous	Indefinite

Key Administration Notes

✔ Take at the same time daily
✔ With or without food (food may reduce nausea)
✔ For women with uterus: Must add progestin (e.g., medroxyprogesterone)

5. INDICATIONS

✅ Moderate-to-severe vasomotor symptoms (hot flashes/night sweats)
✅ Vulvovaginal atrophy (when topical therapy inappropriate)
✅ Prevention of postmenopausal osteoporosis
✅ Hypoestrogenism (primary ovarian failure, surgical menopause)

6. STORAGE CONDITIONS

Temperature: 20-25°C (68-77°F)
Humidity: Keep in original bottle with desiccant
Light Protection: Required
Shelf Life: 3 years

7. KEY RECOMMENDATIONS

✔ Use lowest effective dose for shortest duration
✔ Annual monitoring:

Breast exam/mammogram
Endometrial evaluation (if uterus present)
Lipid profile and bone density (if long-term use)
✔ Consider transdermal estrogen for high-risk patients (VTE history)

8. IMPORTANT SAFETY INFORMATION

Black Box Warnings

⚠ Endometrial Cancer:

5-10x risk increase with unopposed estrogen
Requires progestin co-therapy in non-hysterectomized women

⚠ Cardiovascular Risks:

Increased stroke/MI risk in women >60 years
Higher with oral vs. transdermal formulations

⚠ Breast Cancer:

1.24x risk increase after 5+ years of use

Contraindications

❌ Estrogen-dependent neoplasia
❌ Undiagnosed vaginal bleeding
❌ Active/history of thromboembolism
❌ Severe hepatic dysfunction

Adverse Effects

Common (≥5%)	Serious (<1%)
Breast tenderness	Venous thromboembolism
Nausea	Gallbladder disease
Headache	Dementia (in women >65)

9. COMPARISON WITH OTHER ESTROGENS

Parameter	Premarin	Estradiol	Synthetic Estrogens
Source	Equine	Human-identical	Chemical (e.g., EE)
Components	10+ estrogens	Single compound	Single compound
Bone Protection	+++	+++	+
VTE Risk	High	Moderate	Highest

10. PATIENT COUNSELING POINTS

✔ Take missed dose ASAP (unless close to next dose)
✔ Report warning signs immediately:

Breast lumps
Severe headaches
Visual changes
Leg pain/swelling
✔ Non-hormonal alternatives:
SSRIs (for hot flashes)
Bisphosphonates (for osteoporosis)

CONCLUSION

Reviews

There are no reviews yet.

Be the first to review “PREMARIN TEBLET”

Description
Reviews (0)

Brand Name: Premarin
Generic Name: Conjugated Estrogens (USP)
Therapeutic Class: Estrogen Replacement Therapy (ERT)
Available Strengths: 0.3 mg, 0.45 mg, 0.625 mg, 0.9 mg, 1.25 mg tablets
Source: Natural estrogens derived from pregnant mares’ urine

2. COMPOSITION

Component	Percentage	Primary Estrogenic Activity
Sodium Estrone Sulfate	50-65%	Weak estrogen
Sodium Equilin Sulfate	20-35%	Moderate estrogen
Other Estrogens (Δ8,9-dehydroestrone)	15-25%	Variable activity

*Note: Contains 10+ estrogenic compounds not found in humans*

3. MECHANISM OF ACTION

Binds to nuclear estrogen receptors (ERα and ERβ)
Genomic effects:
- Upregulates protein synthesis in target tissues
- Maintains secondary sexual characteristics
Non-genomic effects:
- Modulates neurotransmitter activity (hot flash reduction)
- Maintains bone mineral density (osteoporosis prevention)

4. DOSAGE & ADMINISTRATION

Standard Dosing Guidelines

Indication	Starting Dose	Maintenance Dose	Duration
Vasomotor Symptoms	0.3-0.45 mg	Lowest effective dose	≤5 years
Vulvovaginal Atrophy	0.3 mg	May increase to 0.625 mg	Ongoing
Osteoporosis Prevention	0.3-0.625 mg	Long-term (with reevaluation)	≥5 years
Hypoestrogenism	0.3-1.25 mg	Cyclic or continuous	Indefinite

Key Administration Notes

✔ Take at the same time daily
✔ With or without food (food may reduce nausea)
✔ For women with uterus: Must add progestin (e.g., medroxyprogesterone)

5. INDICATIONS

✅ Moderate-to-severe vasomotor symptoms (hot flashes/night sweats)
✅ Vulvovaginal atrophy (when topical therapy inappropriate)
✅ Prevention of postmenopausal osteoporosis
✅ Hypoestrogenism (primary ovarian failure, surgical menopause)

6. STORAGE CONDITIONS

Temperature: 20-25°C (68-77°F)
Humidity: Keep in original bottle with desiccant
Light Protection: Required
Shelf Life: 3 years

7. KEY RECOMMENDATIONS

✔ Use lowest effective dose for shortest duration
✔ Annual monitoring:

Breast exam/mammogram
Endometrial evaluation (if uterus present)
Lipid profile and bone density (if long-term use)
✔ Consider transdermal estrogen for high-risk patients (VTE history)

8. IMPORTANT SAFETY INFORMATION

Black Box Warnings

⚠ Endometrial Cancer:

5-10x risk increase with unopposed estrogen
Requires progestin co-therapy in non-hysterectomized women

⚠ Cardiovascular Risks:

Increased stroke/MI risk in women >60 years
Higher with oral vs. transdermal formulations

⚠ Breast Cancer:

1.24x risk increase after 5+ years of use

Contraindications

❌ Estrogen-dependent neoplasia
❌ Undiagnosed vaginal bleeding
❌ Active/history of thromboembolism
❌ Severe hepatic dysfunction

Adverse Effects

Common (≥5%)	Serious (<1%)
Breast tenderness	Venous thromboembolism
Nausea	Gallbladder disease
Headache	Dementia (in women >65)

9. COMPARISON WITH OTHER ESTROGENS

Parameter	Premarin	Estradiol	Synthetic Estrogens
Source	Equine	Human-identical	Chemical (e.g., EE)
Components	10+ estrogens	Single compound	Single compound
Bone Protection	+++	+++	+
VTE Risk	High	Moderate	Highest

10. PATIENT COUNSELING POINTS

✔ Take missed dose ASAP (unless close to next dose)
✔ Report warning signs immediately:

Breast lumps
Severe headaches
Visual changes
Leg pain/swelling
✔ Non-hormonal alternatives:
SSRIs (for hot flashes)
Bisphosphonates (for osteoporosis)

CONCLUSION

Reviews

There are no reviews yet.

Be the first to review “PREMARIN TEBLET”

Medical Disclaimer

Anteka Pharmacy primary intention is to ensure that its consumers get information that is reviewed by experts, accurate and trustworthy. The information and contents of this website are for informational purposes only. They are not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please seek the advice of your doctor and discuss all your queries related to any disease or medicine. Do not disregard professional medical advice or delay in seeking it because of something you have read on Anteka Pharmacy. Our mission is to support, not replace, the doctor-patient relationship.